Endocan - the new endothelial activation marker independently associated with soluble endothelial adhesion molecules in uraemic patients with cardiovascular disease

Clinical Biochemistry

Volumn 48, Issue 6, 2015, Pages 425-430

  Pawlak, Krystyna ^a   Mysliwiec, Michal ^a   Pawlak, Dariusz ^b  

^a Department of Monitored Pharmacotherapy ^*  (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Cardiovascular disease; Chronic kidney disease; Endocan; SICAM 1; SVCAM 1

Indexed keywords

BIOLOGICAL MARKER; ESM1 PROTEIN, HUMAN; INTERCELLULAR ADHESION MOLECULE 1; PROTEOGLYCAN; TUMOR PROTEIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; BLOOD; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; FEMALE; HUMAN; MALE; MIDDLE AGED; UREMIA;

ADULT; BIOMARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTEOGLYCANS; RENAL INSUFFICIENCY, CHRONIC; UREMIA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84939974856     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.01.006     Document Type: Article

References (29)

1. Zoccali C., Mallamaci F., Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int 2003, 85:S105-S110.
2. Stenvinkel P., Pecoits-Filho R., Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 2003, 14:1927-1939.
3. Moody W.E., Edwards N.C., Madhani M., Chue C.D., Steeds R.P., Ferro C.J., et al. Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association?. Atherosclerosis 2012, 223:86-94.
4. Stam F., van Guldener C., Becker A., Dekker J.M., Heine R.J., Bouter L.M., et al. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. J Am Soc Nephrol 2006, 17:537-545.
5. Blankenberg S., Barbaux S., Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003, 170:191-203.
6. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999, 138:S419-S420.
7. Pigott R., Dillon L.P., Hemingway I.H., Gearing A.J. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatant of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992, 187:584-589.
8. Sarrazin S., Adam E., Lyon M., Depontieu F., Motte V.C., Landolfi C., et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006, 1765:25-37.
9. Béchard D., Scherpereel A., Hammad H., Gentina T., Tsicopoulos A., Aumercier M., et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 2001, 167:3099-3106.
10. Tadzic R., Mihalj M., Vcev A., Ennen J., Tadzic A., Drenjancevic I. The effects of arterial blood pressure reduction on endocan and soluble endothelial cell adhesion molecules (CAMs) and CAMs ligands expression in hypertensive patients on Ca-channel blocker therapy. Kidney Blood Press Res 2013, 37:103-115.
11. Lee W., Ku S.-K., Kim S.-W., Bae J.-S. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol 2014, 229:620-630.
12. Pawlak K., Kowalewska A., Mysliwiec M., Pawlak D. Kynurenine and its metabolites-kynurenic acid and anthranilic acid are associated with soluble endothelial adhesion molecules and oxidative status in patients with chronic kidney disease. Am J Med Sci 2009, 338:293-300.
13. Stenvinkel P., Lindholm B., Heimbürger M., Heimbürger O. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant 2000, 15:1624-1630.
14. Pawlak K., Myśliwiec M., Pawlak D. Kynurenine pathway - a new link between endothelial dysfunction and carotid atherosclerosis in chronic kidney disease patients. Adv Med Sci 2010, 55:196-203.
15. Papagianni A., Dovas S., Bantis C., Belechri A.M., Kalovoulos M., Dimitriadis C., et al. Carotid atherosclerosis and endothelial cell adhesion molecules as predictors of long-term outcome in chronic hemodialysis patients. Am J Nephrol 2008, 28:265-274.
16. Papagianni A., Kokolina E., Kalovoulos M., Vainas A., Dimitriadis C., Memmos D. Carotid atherosclerosis is associated with inflammation, malnutrition and intercellular adhesion molecule-1 in patients on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2004, 19:1258-1263.
17. Papagianni A., Kalovoulos M., Kirmizis D., Vainas A., Belechri A.M., Alexopoulos E., et al. Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients. Nephrol Dial Transplant 2003, 18:113-119.
18. Suliman M.E., Qureshi A.R., Heimbürger O., Lindholm B., Stenvinkel P. Soluble adhesion molecules in end-stage renal disease: a predictor of outcome. Nephrol Dial Transplant 2006, 21:1603-1610.
19. Yilmaz M.I., Siriopol D., Saglam M., Kurt Y.G., Unal H.U., Eyileten T., et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int 2014, 86:1213-1220.
20. Su Y.-H., Shu K.-H., Hu C.-P., Cheng C.-H., Wu M.-J., Yu T.-M., et al. Serum endocan correlated with stage of chronic kidney disease and deterioration in renal transplant recipients. Transplant Proc 2014, 46:323-327.
21. National Kidney Fundation K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S76-S92.
22. Balta I., Balta S., Demirkol S., Mikhailidis D.P., Celik T., Akhan M., et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol 2013, 169:1066-1070.
23. Blandizzi C., Gionchetti P., Armuzzi A., Caporali R., Chimenti S., Cimaz R., et al. The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases. Int J Immunopathol Pharmacol 2014, 27(1 Suppl.):1-10.
24. Yamanishi H., Iyama S., Yamaguchi Y., Kanakura Y., Iwatani Y. Relation between iron content of serum ferritin and clinical status factors extracted by factor analysis in patients with hyperferritinemia. Clin Biochem 2002, 35:523-529.
25. Kiechl S., Willeit J., Egger G., Poewe W., Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation 1997, 96(10):3300-3307.
26. Pourmoghaddas A., Sanei H., Garakyaraghi M., Esteki-Ghashghaei F., Gharaati M. The relation between body iron store and ferritin, and coronary artery disease. ARYA Atheroscler 2014, 10:32-36.
27. Gouri A., Dekaken A. Association of oxidative stress and cardiovascular risk in hemodialysis patients: role of ferritin. Cardiovasc Res Suppl 2014, 103:S57-S94.
28. Fishbane S., Kalantar-Zadeh K., Nissenson A.R. Serum ferritin in chronic kidney disease: reconsidering the upper limit for iron treatment. Semin Dial 2004, 17:336-341.
29. Lukaszyk E., Malyszko J. Iron and inflammation in renal diseases. Przegl Lek 2014, 71:95-97.